Literature DB >> 7907318

Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells.

M Hegen1, H W Mittrücker, R Hug, H U Demuth, K Neubert, A Barth, B Fleischer.   

Abstract

CD26 is a proteolytic enzyme (dipeptidylpeptidase IV) expressed on the T cell surface that defines an alternative activation signal for human T lymphocytes. Crosslinking of CD26 via monoclonal antibodies triggers proliferation and cytotoxicity in preactivated T cells. In this study, we used highly specific competitive and irreversible inhibitors of dipeptidylpeptidase IV to study the role of the enzymatic activity in activation of CD26-transfected T cells as well as of CD26-expressing normal human T cell clones. These inhibitors at concentrations that blocked up to 95% of the enzymatic activity, did not specifically inhibit T cell activation neither via TCR/CD3 nor via CD26 itself. This demonstrates that the enzymatic activity of CD26 is not required for its T cell activating properties.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7907318     DOI: 10.1016/S0171-2985(11)80419-5

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  5 in total

Review 1.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

2.  Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

Authors:  Kalpit A Vora; Gene Porter; Roche Peng; Yan Cui; Kellyann Pryor; George Eiermann; Dennis M Zaller
Journal:  BMC Immunol       Date:  2009-04-09       Impact factor: 3.615

Review 3.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

Review 4.  Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.

Authors:  Erin E Mulvihill; Daniel J Drucker
Journal:  Endocr Rev       Date:  2014-09-12       Impact factor: 19.871

5.  Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome.

Authors:  Mohammad Houshmand; Francesca Garello; Rachele Stefania; Valentina Gaidano; Alessandro Cignetti; Michela Spinelli; Carmen Fava; Mahin Nikougoftar Zarif; Sara Galimberti; Ester Pungolino; Mario Annunziata; Luigia Luciano; Giorgina Specchia; Monica Bocchia; Gianni Binotto; Massimiliano Bonifacio; Bruno Martino; Patrizia Pregno; Fabio Stagno; Alessandra Iurlo; Sabina Russo; Silvio Aime; Paola Circosta; Giuseppe Saglio
Journal:  Cancers (Basel)       Date:  2021-03-15       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.